IPX-Vaccine

**IPX-Vaccine** is an investigational, patient-individualized therapeutic peptide cancer vaccine developed by University Hospital Tuebingen for pediatric and adolescent/young-adult patients with metastatic fusion-driven sarcomas after standard treatment. Each vaccine is designed using tumor and normal-tissue sequencing and includes a class II fusion-breakpoint peptide derived from the patient's sarcoma-specific gene fusion and a mutation-derived neoantigen peptide selected from patient-specific nonsynonymous tumor mutations. The peptide components are administered subcutaneously with the Toll-like receptor 1/2 agonist adjuvant XS15, formulated in Montanide ISA 51 VG, to induce tumor-specific T-cell responses. It is being evaluated in the open-label phase I/II PerVision trial in Ewing sarcoma, alveolar rhabdomyosarcoma, and synovial sarcoma.

Other names

Individualized Peptide VaccineIPX vaccinePeptide vaccine IPX